Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

By sjmartinez • March 27, 2025

Channick R, Medrek S, Delcroix M, Gaine S, Jansa P, Lang I, McLaughlin V, Mehta S, Pulido T, Sastry B, Souza R, Torbicki A, Zhao C, Strachan P, Agron P, Yen J, Sitbon O. Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension. JHLT Open. 2025 Jan 16;7:100197. doi: 10.1016/j.jhlto.2024.100197. PMID: 40144855; PMCID: PMC11935431.

Tags: GRIPHON, Macitentan, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, Selexipag, SERAPHIN

Related Posts

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

The protein deacetylase SIRT2 exerts metabolic control over adaptive Beta cell proliferation

Wortham M, Ramms B, Zeng C, Benthuysen JR, Sai S, Pollow DP, Liu F, Schlichting M, Harrington AR, Liu B, Prakash TP, Pirie EC, Zhu[...]

Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson[...]